Sarizotan (EMD 128130) is an orally active serotonin 5-HT 1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC 50 values of 6.5 nM (rat 5-HT 1A ), 0.1 nM (human 5-HT 1A ), 15.1 nM (rat D 2 ), 17 nM (human D 2 ), 6.8 nM (human D 3 ) and 2.4 nM (human D 4.2 ), respectively In Vitro Sarizotan concentration-dependently inhibits the electrically-induced contractions with an IC 50 value of 150 nM (E max 40% at 1 mM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Sarizotan (3, 10 mg/kg, po) at the higher dose slightly decreases 5-HT in the striatum and its metabolite 5-HIAA in frontal cortex and hippocampus. Sarizotan (10 mg/kg, po) substantially increases the DA metabolites DOPAC and HVA in the striatum and frontal cortex . Sarizotan represents a new approach for the treatment of extrapyramidal motor complications such as l-DOPA-induced dyskinesia in Parkinson’s disease . Sarizotan (10 ng and 1 μg, local administration) attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats weighing 220-240 g (exhibiting a vigorous rotational response). Dosage: 1 ng, 10 ng and 1 μg in 0.3 μL solution. Administration: Administered via an injection cannula inserted to the guide cannula through the STN (V -8.4 mm from skull) with the injection cannula connected to a 10-μL syringe and mounted on a microinfusion pump for 22 consecutive days. Result: On day 23, the subthalamic administration of Sarizotan at the higher doses tested (10 ng and 1 μg) significantly decreased the total dyskinesia score in levodopa-treated rats in comparison with the rats treated only with levodopa (p IC50& Target:5-HT 1A Receptor 6.5 nM (IC 50 , rat) 5-HT 1A Receptor 0.1 nM (IC 50 , human) rD 2 Receptor 15.1 nM (IC 50 , rat) D 3 Receptor 6.8 nM (IC 50 , human) 5-HT 1B Receptor 600 nM (IC 50 , rat) 5-HT 1D Receptor 500 nM (IC 50 , calf) 5-HT 2A Receptor 960 nM (IC 50 , rat, agonist site) 5-HT 2A Receptor 587 nM (IC 50 , human, antagonist site) 5-HT 2B Receptor 108 nM (IC 50 , human) 5-HT 2C Receptor 800 nM (IC 50 , pig) 5-HT 3 Receptor 3500 nM (IC 50 , NG 108 cells) 5-HT 5A Receptor 313 nM (IC 50 , human) 5-HT 6 Receptor 3300 nM (IC 50 , human) 5-HT 7 Receptor 10 nM (IC 50 , human) hD 4.2 Receptor 2.4 nM (IC 50 ) hD 2 Receptor 17 nM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Sarizotan
CAS number：351862-32-3(DMSO) molecular formula：C22H21FN2O
overview
compound introduction
Specs
| Chinese alias | 沙利佐坦 | ||
| English alias | - | ||
| CAS number | 351862-32-3(DMSO) | molecular formula | C22H21FN2O |
| molecular weight | 348.41 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
